Administration on Intellectual and Developmental Disabilities, President's Committee for People With Intellectual Disabilities, 12610 [2017-04165]
Download as PDF
<![CDATA[
12610
Federal Register / Vol. 82, No. 42 / Monday, March 6, 2017 / Notices
Studies where differences in potassium
intake or values are confounded with
alteration of other nutrient levels will be
excluded.
IV. Outcomes
V. Timing
A. Studies reporting exclusively on
kidney stone formation need to follow
participants for at least five years,
studies reporting exclusively on kidney
disease need to follow participants for at
least two years, studies reporting
exclusively on cardiovascular disease or
stroke need to follow patients for at least
12 months; all other studies need to
report on an exposure period of at least
four weeks to be eligible.
asabaliauskas on DSK3SPTVN1PROD with NOTICES
VI. Setting
A. Studies in community-dwelling
participants will be eligible.
VII. Study Design
A. Prospective cohort studies and
nested case-control studies, where at
least two groups are compared based on
measured potassium intake or
biomarker values will be eligible.
Retrospective studies, case series, cross-
19:24 Mar 03, 2017
Sharon B. Arnold,
Acting AHRQ Director.
[FR Doc. 2017–04193 Filed 3–3–17; 8:45 am]
A. Studies reporting on mortality (allcause, CVD, CHD, or renal);
cardiovascular disease morbidity,
including coronary heart disease (CHD),
acute coronary syndrome (unstable
angina and myocardial infarction),
stroke, myocardial infarction (STsegment elevation myocardial infarction
[STEMI] and non-ST elevation
myocardial infarction [NSTEMI]),
requiring coronary revascularization
procedures (angioplasty, coronary stent
placement, coronary artery bypass),
other atherosclerotic revascularization
procedures (carotid endarterectomy),
left ventricular hypertrophy,
hospitalization for heart failure, or
hospitalization for any cause of
coronary heart disease or cardiovascular
disease, or combined CVD morbidity
and mortality; or reporting on renal
function intermediary and clinical
outcomes including creatinine clearance
(CrCl), serum creatinine (SCr),
glomerular filtration rate (GFR), end
stage renal disease, chronic kidney
disease (CKD), albuminuria/proteinuria
(including urine albumin-to-creatinine
ratio, urine albumin dipstick level,
urine protein-to-creatinine ratio,
albumin excretion rate), kidney stone
incidence, or acute kidney injury will be
eligible. Studies that do not report
baseline data on the outcomes of
interest will be excluded.
VerDate Sep<11>2014
sectional studies or surveys, and case
reports will be excluded.
Jkt 241001
BILLING CODE 4160–90–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Community Living
Administration on Intellectual and
Developmental Disabilities, President’s
Committee for People With Intellectual
Disabilities
Administration for Community
Living, HHS.
ACTION: Notice.
AGENCY:
Thursday, March 23, 2017 from
8:30 a.m. to 5:00 p.m.; and Friday,
March 24, 2017 from 9:00 a.m. to 3:00
p.m.
These meetings will be open to the
general public.
ADDRESSES: These meetings will be held
in U.S. Department of Health and
Human Services/Hubert H. Humphrey
Building located at 200
IndependenceAvenue SW., Conference
Room 705A, Washington, DC 20201.
Individuals who would like to
participate via conference call may do
so by dialing toll-free #: 1–800–779–
4694, when prompted enter pass code:
4511687. Individuals whose full
participation in the meeting will require
special accommodations (e.g., sign
language interpreting services, assistive
listening devices, materials in
alternative format such as large print or
Braille) should notify Ms. Allison Cruz,
Director, Office of Innovation, via email
at Allison.Cruz@acl.hhs.gov, or via
telephone at 202–795–7334, no later
than Monday, March 6, 2017. The
PCPID will attempt to accommodate
requests made after this date, but cannot
guarantee the ability to grant requests
received after the deadline. All meeting
sites are barrier free, consistent with the
Americans with Disabilities Act (ADA)
and the Federal Advisory Committee
Act (FACA).
AGENDA: The Committee Members will
discuss preparation of the PCPID 2017
Report to the President, including its
content and format, and related data
collection and analysis required to
complete the writing of the Report.
ADDITIONAL INFORMATION: For further
information, please contact Ms. Allison
Cruz, Director, Office of Innovation, 330
C Street SW., Switzer Building, Room
1114, Washington, DC 20201.
DATES:
PO 00000
Frm 00078
Fmt 4703
Sfmt 4703
Telephone: 202–795–7334. Fax: 202–
795–7334. Email: Allison.Cruz@
acl.hhs.gov.
SUPPLEMENTARY INFORMATION: The
PCPID acts in an advisory capacity to
the President and the Secretary of
Health and Human Services on a broad
range of topics relating to programs,
services and support for individuals
with intellectual disabilities. The PCPID
executive order stipulates that the
Committee shall: (1) Provide such
advice concerning intellectual
disabilities as the President or the
Secretary of Health and Human Services
may request; and (2) provide advice to
the President concerning the following
for people with intellectual disabilities:
(A) Expansion of educational
opportunities; (B) promotion of
homeownership; (C) assurance of
workplace integration; (D) improvement
of transportation options; (E) expansion
of full access to community living; and
(F) increasing access to assistive and
universally designed technologies.
Dated: February 27, 2017.
Bob Williams,
Acting Designated Federal Official, PCPID,
Administration on Disabilities (AoD).
[FR Doc. 2017–04165 Filed 3–3–17; 8:45 am]
BILLING CODE 4154–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Community Living
Agency Information Collection
Activities; Proposed Collection; Public
Comment Request; Extension of a
Currently Approved Information
Collection (ICR–REV); Centers for
Independent Living Annual
Performance Report (CILPPR);
Correction
Independent Living
Administration, Administration for
Community Living, HHS.
ACTION: Notice of correction.
AGENCY:
The Administration for
Community Living published a
proposed collection of information
document in the Federal Register on
February 23, 2017. (82 FR 11471 and
11472) The document contained an
incorrect date and email address. In
addition under the heading ‘‘New
Requirements’’, the first paragraph was
revised.
FOR FURTHER INFORMATION CONTACT:
Corinna Styles, 202–795–7446.
Corrections:
Under the DATES section, page 11471,
column two, correct the notice to read:
‘‘Submit written or electronic comments
SUMMARY:
E:\FR\FM\06MRN1.SGM
06MRN1
]]>Agencies
[Federal Register Volume 82, Number 42 (Monday, March 6, 2017)]
[Notices]
[Page 12610]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-04165]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Administration for Community Living
Administration on Intellectual and Developmental Disabilities,
President's Committee for People With Intellectual Disabilities
AGENCY: Administration for Community Living, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
DATES: Thursday, March 23, 2017 from 8:30 a.m. to 5:00 p.m.; and
Friday, March 24, 2017 from 9:00 a.m. to 3:00 p.m.
These meetings will be open to the general public.
ADDRESSES: These meetings will be held in U.S. Department of Health and
Human Services/Hubert H. Humphrey Building located at 200
IndependenceAvenue SW., Conference Room 705A, Washington, DC 20201.
Individuals who would like to participate via conference call may do so
by dialing toll-free #: 1-800-779-4694, when prompted enter pass code:
4511687. Individuals whose full participation in the meeting will
require special accommodations (e.g., sign language interpreting
services, assistive listening devices, materials in alternative format
such as large print or Braille) should notify Ms. Allison Cruz,
Director, Office of Innovation, via email at Allison.Cruz@acl.hhs.gov,
or via telephone at 202-795-7334, no later than Monday, March 6, 2017.
The PCPID will attempt to accommodate requests made after this date,
but cannot guarantee the ability to grant requests received after the
deadline. All meeting sites are barrier free, consistent with the
Americans with Disabilities Act (ADA) and the Federal Advisory
Committee Act (FACA).
AGENDA: The Committee Members will discuss preparation of the PCPID
2017 Report to the President, including its content and format, and
related data collection and analysis required to complete the writing
of the Report.
ADDITIONAL INFORMATION: For further information, please contact Ms.
Allison Cruz, Director, Office of Innovation, 330 C Street SW., Switzer
Building, Room 1114, Washington, DC 20201. Telephone: 202-795-7334.
Fax: 202-795-7334. Email: Allison.Cruz@acl.hhs.gov.
SUPPLEMENTARY INFORMATION: The PCPID acts in an advisory capacity to
the President and the Secretary of Health and Human Services on a broad
range of topics relating to programs, services and support for
individuals with intellectual disabilities. The PCPID executive order
stipulates that the Committee shall: (1) Provide such advice concerning
intellectual disabilities as the President or the Secretary of Health
and Human Services may request; and (2) provide advice to the President
concerning the following for people with intellectual disabilities: (A)
Expansion of educational opportunities; (B) promotion of homeownership;
(C) assurance of workplace integration; (D) improvement of
transportation options; (E) expansion of full access to community
living; and (F) increasing access to assistive and universally designed
technologies.
Dated: February 27, 2017.
Bob Williams,
Acting Designated Federal Official, PCPID, Administration on
Disabilities (AoD).
[FR Doc. 2017-04165 Filed 3-3-17; 8:45 am]
BILLING CODE 4154-01-P
